Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application.

JCO Clin Cancer Inform 2019 07;3:1-10

MD Anderson Cancer Center, Houston, TX.

Purpose: To understand the quality of life (QoL) for patients with neuroendocrine tumors (NETs) through comparison of QoL questionnaires and symptom tracking as well as journaling via the Carcinoid NETs Health Storylines mobile application (app).

Patients And Methods: This was a 12-week prospective, observational study of US patients with NET who were taking long-acting somatostatin analogs. National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) and European Organisation for Research and Treatment of Cancer (EORTC) questionnaires were administered three times. Patients also monitored symptoms, mood, bowel movements, food, activity, and sleep, and they journaled in their app, which was coded by theme and sentiment for qualitative analysis.

Results: Of the 120 patients with NET, 78% were women (mean age, 57 years); 76% had gastroenteropancreatic NETs, and 88% had metastases. Lanreotide depot and octreotide long-acting release (LAR) were used by 41% and 59%, respectively. The most common symptoms at baseline were fatigue (76.7%), diarrhea (62.5%), abdominal discomfort (64.1%), and trouble sleeping (57.5%). The majority completed five of six survey assessments (median, 5; mean, 5.1) and tracked four symptoms in the app (median, 4; mean, 5.5); the average frequency was 41.6 days for each symptom (median, 43; mean, 41.6; range, 1 to 84 days [12 weeks]). Without treatment change, most EORTC-assessed physical symptoms decreased from baseline to midpoint (eg, 59.3% at baseline 33% at midpoint reported "quite a bit" or "very much" diarrhea; = .002). App-based symptom tracking revealed large day-to-day variation, but weekly averages correlated well with survey scores. Journal entries showed that more patients made predominantly negative unsolicited entries about their injection experience with octreotide LAR compared with lanreotide (13 of 17 two of 13; < .001).

Conclusion: Patients with NET experience a large symptom burden that varies daily. A decrease in physical symptoms on QoL surveys suggests an effect from daily app-based monitoring or journaling, which may reduce recall bias and benefit the patient's experience of symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.19.00025DOI Listing
July 2019
2 Reads

Publication Analysis

Top Keywords

patients net
12
mobile application
8
neuroendocrine tumors
8
quality life
8
symptom tracking
8
physical symptoms
8
patients
6
symptoms
6
tracked symptoms
4
median tracked
4
symptoms app
4
median average
4
app median
4
survey assessments
4
575% majority
4
sleeping 575%
4
majority completed
4
completed survey
4
trouble sleeping
4
assessments median
4

Similar Publications